About Ocular Therapeutix
Ocular Therapeutix is a publicly listed company based in Bedford (United States) founded in 2006. Ophthalmic therapeutics for eye diseases are developed using hydrogel technology. Ocular Therapeutix has raised $89.45 million across 8 funding rounds from investors including Baxter, Ascension Ventures and Polaris Partners. The company has 274 employees. Its website ocutx.com draws about 13 thousand monthly visits. Ocular Therapeutix offers products and services including DEXTENZA, AXPAXLI, PAXTRAVA, and ReSure Sealant. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is Ocular Therapeutix, Inc. Its competitors include Kriya Therapeutics, Annexon and Aldeyra; 3 of its 3 listed competitors have raised funding.
Company details
Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, United States. Operations center on the development and commercialization of therapies for ocular conditions through a proprietary hydrogel platform. Products include ReSure Sealant for sealing corneal incisions post-cataract surgery, along with treatments for post-surgical inflammation, pain, allergic conjunctivitis, glaucoma, and dry eye disease. An injectable anti-VEGF therapy for eye diseases is also under development.
- Annual Revenue$51.95 M (USD)-18.47as on Dec 31, 2025
- Net Profit-$265.94 M (USD)-37.43as on Dec 31, 2025
- EBITDA-$265.69 M (USD)-58.16as on Dec 31, 2025
- Total Equity Funding$89.45M (USD)
in 8 rounds
- Latest Funding Round$8.5M (USD), Series D
Jun 2013
- InvestorsBaxter
& 6 more
- Employee Count274
Products & Services of Ocular Therapeutix
Ocular Therapeutix offers a comprehensive portfolio of products and services, including DEXTENZA, AXPAXLI, PAXTRAVA, and ReSure Sealant.
Sustained-release insert for treating eye inflammation and pain.
Delivers axitinib to manage retinal diseases effectively.
Provides travoprost for glaucoma treatment over time.
Used to seal wounds in ocular surgeries securely.
Funding Insights of Ocular Therapeutix
Ocular Therapeutix has successfully raised a total of $89.45M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $8.5 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $89.45M
- Total Rounds 8
- Last Round Series D — $8.5M
- Investors Count 7
All 8 funding rounds of Ocular Therapeutix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2013 | $8.5M | Series D | – | – | |
| Jan 2013 | $23.8M | Series D | – | – | |
| Feb 2011 | $14M | Series D | – | Ascension Ventures, SV Health Investors | |
| Jan 2011 | $21M | Series C | – | Polaris Partners, Versant Ventures | – |
| Jun 2009 | $15M | Series B | – | – | – |
| Jan 2008 | $6M | Series A | – | – | – |
| Oct 2006 | $1.15M | Seed | – | – | – |
| Jun 2006 | Seed | – | – |
7 investors in total: 7 institutional.
Investors in Ocular Therapeutix
Ocular Therapeutix has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Baxter, Ascension Ventures and Polaris Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Strategic investments in healthcare technologies and data innovations. | ascensionventures.org | |||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
| sparta-llc.com | ||||
Medical innovations are accelerated from concept to commercialization by Incept. | inceptllc.com | Bedford, USA | ||
Biosciences, medication delivery, and renal products are developed and marketed. | 1931 | baxter.com | Deerfield, United States |
Investor details for Ocular Therapeutix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ocular Therapeutix
98 people are tracked at Ocular Therapeutix (38 in leadership, 5 in board & advisors, 55 in team); the tracked headcount is 274.
| Name | Role | Group |
|---|---|---|
Kathleen Theriault | Director Of Accounting & External Reporting | Leadership |
Trung Tran | Director, Medical Director Team | Leadership |
Cartney Smith | Director, Pharmaceutical Development | Leadership |
Wesley Araujo | Associate Director, Medical Collaborations & Marketing Operations Lead | Leadership |
Jason Assaad | Associate Director, Strategy & Investor Relations | Leadership |
Dean M. Donato | Director, Commercial Marketing | Leadership |
Donald Notman | Chief Financial Officer | Leadership |
Gretchen Alleman | Regional Sales Director | Leadership |
Alyssa Paolini (Montieth) | Director, Medical Affairs | Leadership |
Peter Jarrett | Chief Technical Officer | Leadership |
Paul Adams | Director, Federal Government Accounts | Leadership |
Christopher White | Chief Business Officer | Leadership |
Joshua Smith | Executive Director, Marketing And Operations | Leadership |
Jaime Keefe | Regional Sales Director - South | Leadership |
Kevin Jones | Sales Director | Leadership |
Owen Bishop | Vice President, Market Access | Leadership |
Dinesh Haswani | Head Product Development Drug Device Combination Products | Leadership |
Matthew Callewaert O.d. | Director Clinical Development | Leadership |
Srilatha Vantipalli | Sr. Director, Internal Medical Affairs | Leadership |
Matthew Cheung Pharmd | Director, Medical Collaborations | Leadership |
78 more people are available in the full profile.
Complete people profiles for Ocular Therapeutix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ocular Therapeutix
Ocular Therapeutix is a publicly listed company on the NASDAQ with ticker symbol OCUL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jul 2014
- Listed onNASDAQ: OCUL
- Listed entityOcular Therapeutix, Inc.
- Exchange sectorHealth technology
- ISINUS67576A1007
- Share price$7.24 (-4.23% on the day) · 2026-10-13
- Market capitalisation$1.59B
- EPS (diluted, trailing year)$-1.41
- Volume (last session)3,216,271
Financials of Ocular Therapeutix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $52.0M | -$265.9M | -$265.7M |
| 2024 | $63.7M | -$193.5M | -$168.0M |
| 2023 | $58.4M | -$80.7M | -$79.4M |
| 2022 | $51.5M | -$71.0M | -$76.5M |
| 2021 | $43.5M | -$6.5M | -$75.6M |
Detailed financial statements for Ocular Therapeutix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ocular Therapeutix
4 dated milestones of Ocular Therapeutix across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ocular Therapeutix is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $8.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of Ocular Therapeutix
Ocular Therapeutix has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Annexon and Aldeyra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of Ocular Therapeutix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ocular Therapeutix
The website of Ocular Therapeutix (ocutx.com) receives about 12.7K visits a month and ranks #1,928,176 among all websites worldwide, #2,629 in Biotechnology and Pharmaceuticals.
- Monthly visits12.7K
▲ 9.2% vs previous month
- Unique visitors4.8K
per month
- Global rank#1,928,176
among all websites
- Category rank#2,629
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.2
- Average visit2 min 28 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Ocular Therapeutix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| athersys.com | 100% | 1.7K | #8,716,189 | View details | |
| ardelyx.com | 99% | 17.8K | #2,305,983 | View details | |
aco.org.au | aco.org.au | 76% | #1,235,090 | – | |
| modernretina.com | 70% | #1,159,732 | View details | ||
therapeutic-touch.org | therapeutic-touch.org | 61% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Ocular Therapeutix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Ocular Therapeutix (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ocular Therapeutix
Complete news archive for Ocular Therapeutix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ocular Therapeutix
Ocular Therapeutix was founded in 2006.
Ocular Therapeutix is headquartered in Bedford, United States.
Ocular Therapeutix is a funded company, having raised a total of $89.45M across 8 funding rounds to date.
Ocular Therapeutix has 274 employees.
Annual revenue of Ocular Therapeutix is $51.95M as on Dec 31, 2025.
Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, United States. Operations center on the development and commercialization of therapies for ocular conditions through a proprietary hydrogel platform. Products include ReSure Sealant for sealing corneal incisions post-cataract surgery, along with treatments for post-surgical inflammation, pain, allergic conjunctivitis, glaucoma, and dry eye disease. An injectable anti-VEGF therapy for eye diseases is also under development.
Ocular Therapeutix's top competitors include Annexon, Aldeyra and Kriya Therapeutics.
Ocular Therapeutix offers DEXTENZA, AXPAXLI, PAXTRAVA, and ReSure Sealant.
Yes, Ocular Therapeutix is publicly traded on NASDAQ under the ticker symbol OCUL.
Ocular Therapeutix has 7 investors. Key investors include Baxter, Ascension Ventures, Polaris Partners, Versant Ventures, and SV Health Investors.
Ocular Therapeutix operates through Ocular Therapeutix, Inc..